- $31.89bn
- $33.90bn
- $9.89bn
Biogen, Denali scrap Parkinson's drug after failure in mid-to-late stage study (updated)
Biogen, Denali scrap Parkinson's drug after failure in mid-to-late stage study
Street View: Skeptical on experimental Alzheimer's drug, awaits full data
U.S. RESEARCH ROUNDUP- Applied Materials, NVIDIA, Thermo Fisher Scientific
U.S. STOCKS ON THE MOVE-Advanced Energy, Bel Fuse, Cerebras
U.S. STOCKS ON THE MOVE-Klarna, Biogen, Legence
Biogen climbs on plans to advance development of experimental Alzheimer's therapy
Biogen to advance experimental Alzheimer’s drug despite mid-stage trial miss (updated)
Biogen's Alzheimer’s drug fails to meet mid-stage trial goal
Brief: Topline Results From Phase 2 Celia Study Of Diranersen,First Study To Show Reduction In Tau Pathology And Cognitive Benefit In Patients With Early Alzheimer'S Disease
Roche gets second European approval for Alzheimer's test
U.S. STOCKS ON THE MOVE-Corning, BILL Holdings, Moderna
U.S. STOCKS ON THE MOVE-Corning, Moderna, News Corp
U.S. STOCKS ON THE MOVE-Coinbase, Microchip, Wendy's
U.S. STOCKS ON THE MOVE-Cloudflare, IREN, Monster Beverage
Biogen down after US FDA extends review of Alzheimer's drug
Factbox: Global drugmakers rush to boost US presence as tariff threat looms
U.S. STOCKS ON THE MOVE-Biogen, Fair Isaac, General Dynamics
Biogen climbs after quarterly profit beat